Clinical pathologic study on effect of Qianggan capsule in treating patients of chronic hepatitis B with liver cirrhosis

Objective  

To explore the clinical therapeutic effect of Qianggan Capsule (QGC) in treating chronic hepatitis B with liver fibrosis from the pathological aspect.     

抗生素C3221-A的分离及结构鉴定

对嗜热放线菌X3221的发酵液进行溶剂萃取、Sephadex LH-20柱分离、中压控纯化,得到一具有抗菌和抗肿瘤活性的抗生素C3221-A。通过理化性质比较和结构单定确定其为Thermorubin A。     

ZMW型环氧乙烷灭菌箱对骨移植材料灭菌效果的初步观察

目的 :观察ZMW型环氧乙烷灭菌箱对异体骨材料灭菌效果 ,旨在寻找一种安全、经济的灭菌方法。方法 :清洁条件下取骨 ,制成 0 .5cm× 0 .5cm× 2cm湿润骨材料和干燥骨材料 ,抽取样本 ,用ZMW型环氧乙烷灭菌箱 (15 0L)在不同温度及时间下消毒 ,以环氧乙烷指示胶带是否变色作为灭菌指标 ,样本在消毒前后分别作细菌培养。结果 :不同消毒条件下 ,每批样本均有细菌生长 ,干燥骨材料有菌率高于湿润的骨材料。结论 :ZMW型环氧乙烷灭菌箱不能使异体骨移植材料完全达到灭菌的要求 ,环氧乙烷指示胶带不能作为骨移植材料的灭菌指标 ,干燥可能使细菌的抗环氧乙烷能力增加 ,从而间接的影响了环氧乙烷的消毒效果。     

Studies on the effect of tetrandrine on microtubules. I. Biochemical observation and electron microscopy

Microtubules were purified by using two cycles of assembly and disassembly processes on fresh brain homogenates from 30 guinea pigs. The yield was about 60 mg. The effect of tetrandrine on tubulin was determined by spectrophotometric analysis and electron microscopy. In addition, we used the indirect immunofluorescent method including tubulin antibody to locate the presence of microtubules in 3T3 cells by fluorescence microscopy. The effects of colchicine and P204 were studied for comparison at the same time. The results showed that colchicine can effectively depolymerize microtubules, while tetrandrine showed aggregation, and in a different manner. The shape and structure of microtubules were definitely destroyed by colchicine, but were not affected by P204 which protected against the destructive effect of tetrandrine. This result indicated the safety of using a combination of P204 and tetrandrine in the treatment of silicosis.     

血管紧张素转换酶抑制剂在急性心肌梗塞早期的应用

对２５例急性心肌梗塞（ＡＭＩ）并左心功能不全患者早期应用血管紧张素转换酶抑制剂（ＡＣＥＩ）治疗的对照性临床分析，结果：用小剂量的ＡＣＥＩ治疗对患者心率、血压无显著的影响〔治疗前后心率分别为８９．９０±１０．２２次／分与８９．４２±８．１９次／分，血压分别为１５．３７±３．４６／９．７４±２．３２ｋＰａ（１ｋＰａ＝７．５ｍｍＨｇ）〕和１４．９６±２．６０／９．４６±１．７６ｋＰａ〕；对合并轻、中度泵衰竭患者的疗效显著，但对重度泵衰竭的疗效与对照组比较无显著性差异；治疗组恶性心律失常的发生率较对照组减低１３．３８％，警告性室早的发生率治疗组较对照组减少２６．３９％，但Ⅱ°～Ⅲ°房室传导阻滞的发生率治疗组高于对照组；两组４周病死率比较无显著性差异。作者认为：ＡＣＥＩ治疗ＡＭＩ并轻、中度泵衰竭安全有效；ＡＣＥＩ有一定抗心律失常作用，但应注意传导系统的并发症，使用中应注意各种副作用的发生。